Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given “Buy” Rating at HC Wainwright

Arrowhead Pharmaceuticals (NASDAQ:ARWR)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued on Thursday, Benzinga reports. They presently have a $120.00 price target on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential upside of 105.13% from the company’s previous close.

Several other research analysts also recently weighed in on the company. The Goldman Sachs Group began coverage on Arrowhead Pharmaceuticals in a research note on Thursday, September 24th. They issued a “neutral” rating and a $74.00 price target for the company. B. Riley Financial upped their price objective on Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Piper Sandler reaffirmed an “overweight” rating and set a $126.00 price target (up from $110.00) on shares of Arrowhead Pharmaceuticals in a research note on Thursday, July 23rd. Leerink Partners lifted their target price on Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the stock a “market perform” rating in a research report on Wednesday, June 17th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $100.00 price target on shares of Arrowhead Pharmaceuticals in a report on Monday, August 31st. Eleven equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $99.07.

Arrowhead Pharmaceuticals Stock Performance

ARWR stock traded up $0.13 during midday trading on Thursday, reaching $58.50. 2,009,461 shares of the company’s stock traded hands, compared to its average volume of 2,292,497. The company has a current ratio of 5.90, a quick ratio of 5.90 and a debt-to-equity ratio of 1.77. Arrowhead Pharmaceuticals has a 52-week low of $36.57 and a 52-week high of $95.49. The stock has a market cap of $8.24 billion, a P/E ratio of -26.00 and a beta of 1.29. The stock’s 50-day moving average is $76.71 and its 200 day moving average is $75.99.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.13). The business had revenue of $75.25 million for the quarter, compared to analysts’ expectations of $44.17 million. Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%. The company’s revenue was up 171.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.26) EPS. As a group, analysts anticipate that Arrowhead Pharmaceuticals will post -3.62 EPS for the current year.

Insider Activity at Arrowhead Pharmaceuticals

In other news, Director Adeoye Y. Olukotun sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total value of $173,920.00. Following the sale, the director directly owned 31,600 shares of the company’s stock, valued at approximately $2,747,936. The trade was a 5.95% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Michael S. Perry sold 11,600 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the sale, the director directly owned 111,459 shares in the company, valued at approximately $9,730,370.70. The trade was a 9.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 3.60% of the stock is currently owned by company insiders.

Institutional Trading of Arrowhead Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in Arrowhead Pharmaceuticals during the 2nd quarter worth $1,208,838,000. Baker BROS. Advisors LP raised its stake in Arrowhead Pharmaceuticals by 30.2% during the 4th quarter. Baker BROS. Advisors LP now owns 2,175,645 shares of the biotechnology company’s stock valued at $144,441,000 after acquiring an additional 504,883 shares during the last quarter. Siren L.L.C. lifted its position in Arrowhead Pharmaceuticals by 7.7% during the 1st quarter. Siren L.L.C. now owns 1,615,476 shares of the biotechnology company’s stock worth $101,290,000 after acquiring an additional 115,000 shares during the period. Jupiter Topco LLC acquired a new stake in Arrowhead Pharmaceuticals during the 2nd quarter worth approximately $99,623,000. Finally, Janus Henderson Group PLC grew its stake in shares of Arrowhead Pharmaceuticals by 12.2% in the 1st quarter. Janus Henderson Group PLC now owns 1,436,990 shares of the biotechnology company’s stock valued at $90,119,000 after purchasing an additional 156,544 shares during the last quarter. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals News Roundup

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Interim Phase 1/2a results showed up to a 73% reduction in tau, with effects described as deep and durable in healthy volunteers. Arrowhead said the results represent the first clinical validation of its ability to achieve meaningful gene knockdown in the brain, potentially expanding its platform into Alzheimer’s disease and other tauopathies. Arrowhead ARO-MAPT interim clinical data
• Positive Sentiment: Coverage from UBS initiated with a Buy rating and a $109 price target. Chardan Capital reaffirmed Buy with a $115 target, while HC Wainwright reiterated Buy and raised or maintained a $120 target. These targets imply significant potential upside and reinforce positive analyst sentiment.
• Positive Sentiment: Reports characterized ARO-MAPT’s ability to cross the blood-brain barrier as a potentially important platform breakthrough, which could improve Arrowhead’s prospects in its investigational central nervous system pipeline. Arrowhead Alzheimer’s drug crosses the brain barrier
• Neutral Sentiment: The results are early-stage and were reported in healthy volunteers, so the clinical benefit for Alzheimer’s patients remains unproven. Additional trials will be needed to establish efficacy, safety, and durability in patients before commercialization.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company focused on developing medicines that silence disease-causing genes. Its research is based primarily on RNA interference (RNAi), a biological process that reduces the production of specific proteins by targeting messenger RNA before it can be used to make those proteins.

The company uses its proprietary Targeted RNAi Molecule (TRiM) platform to design and deliver RNAi therapeutics to selected tissues, including the liver and lungs.